{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T01:17:21Z","timestamp":1760577441418},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1]]},"abstract":"\n Purpose:<\/jats:title>\n Platinum-derived chemotherapy is one of the cornerstones in the treatment of central nervous system tumors in children. We aimed to assess the incidence of hearing loss in children after the exposure to platinum drugs.<\/jats:p>\n <\/jats:sec>\n \n Material and Methods:<\/jats:title>\n Retrospective study of prospectively collected data on children consecutively diagnosed with brain tumors and treated with platinum derivatives at a tertiary referral hospital between January 2006 and December 2015. We analyzed multiples variables, such as: age at diagnosis, tumor location, hydrocephalus, platinum drug type, radiotherapy, and follow-up time. The final sample size was 51 patients.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n The median age at diagnosis was 6 years. The median overall follow-up time was 75 months. The incidence of ototoxicity was 23.5%. Rates of hearing loss with carboplatinum were lower than with cisplatinum. A statistically significant association occurred between the presence of hydrocephalus, radiotherapy exposure, infratentorial tumor location, and ototoxicity after treatment with platinum derivatives.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Childhood central nervous system tumors nowadays exhibit improved cure and survival rates. However, the ototoxicity resulting from the chemotherapy treatment may accompany patients for the rest of their lives. This study reveals that this occurrence is not negligible, and the association of radiotherapy and the presence of hydrocephalus can be potentiating factors.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/mph.0000000000001637","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T19:25:02Z","timestamp":1572895502000},"page":"e25-e31","source":"Crossref","is-referenced-by-count":16,"title":["Platinum-drugs Ototoxicity in Pediatric Patients With Brain Tumors: A 10-Year Review"],"prefix":"10.1097","volume":"42","author":[{"given":"David","family":"Rabi\u00e7o-Costa","sequence":"first","affiliation":[{"name":"Unit of Otorhinolaryngology, Department of Surgery and Physiology"}]},{"given":"Maria J.","family":"Gil-da-Costa","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Division of Hospital S\u00e3o Jo\u00e3o Center"}]},{"given":"Jos\u00e9 P.","family":"Barbosa","sequence":"additional","affiliation":[{"name":"MEDCIDS (Department of Community Medicine, Information and Decision in Health), Faculty of Medicine, University of Porto"}]},{"given":"Maria","family":"Bom-Sucesso","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Division of Hospital S\u00e3o Jo\u00e3o Center"}]},{"given":"Jorge","family":"Spratley","sequence":"additional","affiliation":[{"name":"Unit of Otorhinolaryngology, Department of Surgery and Physiology"},{"name":"Section of Pediatric Otorhinolaryngology, Department of Otorhinolaryngology, Hospital S\u00e3o Jo\u00e3o University Center"},{"name":"CINTESIS (Center for Health Technology and Services Research), Porto, Portugal"}]}],"member":"276","published-online":{"date-parts":[[2019,11,1]]},"reference":[{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ejpn.2009.12.006","article-title":"Long-term survivors of childhood central nervous system malignancies: the experience of the Childhood Cancer Survivor Study","volume":"14","author":"Armstrong","year":"2010","journal-title":"Eur J Paediatr Neurol"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/pbc.21898","article-title":"Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma","volume":"52","author":"Jehanne","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/pbc.24138","article-title":"Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients","volume":"59","author":"Yancey","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.tips.2013.05.006","article-title":"Understanding platinum-induced ototoxicity","volume":"3","author":"Langer","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1097\/MPH.0000000000000028","article-title":"Cisplatin-induced hearing loss: the need for a long-term evaluating system","volume":"36","author":"Yasui","year":"2014","journal-title":"J Pediatr Hematol Oncol"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/MPH.0b013e31815d1d83","article-title":"Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens","volume":"30","author":"Dean","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1200\/JCO.2011.36.9744","article-title":"Carboplatin-associated ototoxicity in children with retinoblastoma","volume":"30","author":"Qaddoumi","year":"2012","journal-title":"J Clin Oncol"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000442435","article-title":"Audiological monitoring in children treated with platinum chemotherapy","volume":"21","author":"Fetoni","year":"2016","journal-title":"Audiol Neurootol"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/MPH.0b013e3181cb8593","article-title":"Late onset hearing loss: a significant complication of cancer survivors treated with cisplatin containing chemotherapy regimens","volume":"32","author":"Kolinsky","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000468522","article-title":"The role of audiometry prior to high-dose cisplatin in patients with head and neck cancer","volume":"93","author":"Caballero","year":"2017","journal-title":"Oncology"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2009.24.4228","article-title":"Practical grading system for evaluating cisplatin ototoxicity in children","volume":"28","author":"Chang","year":"2010","journal-title":"J Clin Oncol"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1017\/S0022215113000947","article-title":"Mechanisms of cisplatin ototoxicity: theoretical review","volume":"127","author":"Gon\u00e7alves","year":"2012","journal-title":"J Laryngol Otol"},{"key":"R16-20230918","first-page":"e87","article-title":"Cisplatin otoprotection using transtympanic L-N-acetylcysteine: a pilot randomized study in head and neck cancer patients","volume":"124","author":"Yoo","year":"2013","journal-title":"Laryngoscope"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/COC.0b013e31822e006d","article-title":"Transtympanic Injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity. A feasible method with promising efficacy","volume":"36","author":"Riga","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1200\/JCO.2007.14.3974","article-title":"Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma","volume":"26","author":"Fouladi","year":"2008","journal-title":"J Clin Oncol"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/neuonc\/not241","article-title":"Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma","volume":"16","author":"Gurney","year":"2014","journal-title":"Neuro Oncol"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/0194599816678381","article-title":"Mitochondria-targeted antioxidant mitoquinone reduces cisplatin-induced ototoxicity in guinea pigs","volume":"156","author":"Tate","year":"2017","journal-title":"Otolaryngol Head Neck Surg"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/08880018.2017.1323985","article-title":"Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors","volume":"34","author":"Clemens","year":"2017","journal-title":"Pediatr Hematol Oncol"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.heares.2005.03.023","article-title":"The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study","volume":"205","author":"van Ruijven","year":"2005","journal-title":"Hear Res"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","article-title":"Cisplatin: mode of cytotoxic action and molecular basis of resistance","volume":"22","author":"Siddik","year":"2003","journal-title":"Oncogene"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","article-title":"Molecular mechanisms of resistance and toxicity associated with platinating agents","volume":"33","author":"Rabik","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2015.63.6738","article-title":"Hearing loss in patients who received cranial radiation therapy for childhood cancer","volume":"34","author":"Bass","year":"2016","journal-title":"J Clin Oncol"},{"key":"R27-20230918","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/pbc.25123","article-title":"Incidence of platinum-induced ototoxicity in pediatric patients in Quebec","volume":"61","author":"Peleva","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"R28-20230918","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00405-016-4117-z","article-title":"Platinum-induced ototoxicity: a review of prevailing ototoxicity criteria","volume":"274","author":"Waissbluth","year":"2016","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"R29-20230918","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/pbc.26212","article-title":"Long-term auditory complications after childhood cancer: a report from the Swiss Childhood Cancer Survivor Study","volume":"64","author":"Weiss","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"R30-20230918","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/bmb\/63.1.171","article-title":"Auditory development and the role of experience","volume":"63","author":"Moore","year":"2002","journal-title":"Br Med Bull"},{"key":"R31-20230918","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejca.2016.09.023","article-title":"Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study","volume":"69","author":"Clemens","year":"2016","journal-title":"Eur J Cancer"},{"key":"R32-20230918","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/01.mph.0000141348.62532.73","article-title":"Platinum compound-related ototoxicity in children long-term follow-up reveals continuous worsening of hearing loss","volume":"26","author":"Bertolini","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"R33-20230918","doi-asserted-by":"crossref","first-page":"8588","DOI":"10.1200\/JCO.2004.00.5355","article-title":"Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development","volume":"23","author":"Knight","year":"2005","journal-title":"J Clin Oncol"},{"key":"R34-20230918","doi-asserted-by":"crossref","first-page":"925485","DOI":"10.1155\/2014\/925485","article-title":"Prevention and restoration of hearing loss associated with the use of cisplatin","volume":"2014","author":"Chirtes","year":"2014","journal-title":"Biomed Res Int"},{"key":"R35-20230918","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/cam4.516","article-title":"SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma","volume":"4","author":"Brown","year":"2015","journal-title":"Cancer Med"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001637","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:24:53Z","timestamp":1695011093000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001637","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11,1]]}}}